The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region

Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation

(2013) Pauline A van Schouwenburg et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View

(2013) Shi Hu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Structural Basis for Treating Tumor Necrosis Factor α (TNFα)-associated Diseases with the Therapeutic Antibody Infliximab

(2013) Shuaiyi Liang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab

(2013) Geertje J. D. van Mierlo et al.   Journal of Immunotoxicology

The impact of neutralizing antibodies on the risk of disease worsening in interferon β–treated relapsing multiple sclerosis: a 5 year post-marketing study

(2013) D. Paolicelli et al.   JOURNAL OF NEUROLOGY

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation

(2012) Pauline A van Schouwenburg et al.   ANNALS OF THE RHEUMATIC DISEASES

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Exploring the Binding Sites of Anti-Infliximab Antibodies in Pediatric Patients With Rheumatic Diseases Treated With Infliximab

(2010) Miha Kosmač et al.   PEDIATRIC RESEARCH